Medidata announced that CTI Clinical Trial and Consulting Services will use Medidata’s Remote Source Review to power remote monitoring and document review for multiple global studies, including several COVID-19 projects. The COVID-19 pandemic has placed an unprecedented strain on drug and vaccine research because of limitations on travel and access to clinical research sites. (For more information, see COVID-19 and Clinical Trials: The Medidata Perspective.) One way Medidata is supporting the continuation of trials during these times is by aligning its imaging workflow solution to rapidly, securely, and remotely assist researchers in critical document acquisition and source document review. Medidata Remote Source Review, a quick-to-implement technology built on Medidata's industry-leading Rave Imaging system, is already deployed in more than 15,000 clinical sites. This 21 CFR Part 11 compliant solution is especially valuable when studies have critical timelines, and there are no secure options to collect, review, de-identify, and redact Personally Identifiable Information (PII). Less secure, antiquated tools such as fax, email, video, and file sharing software solutions place timelines and data integrity at risk. Remote Source Review also helps improve clinical research associate (CRA) productivity by decreasing travel time and costs.